FXS5626 clinical trials
How each study uses FXS5626 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the FXS5626 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- FXS5626 tablet
- 2
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test FXS5626, phase 3 first.
- Nov 2027Phase II/III Study of FXS5626 in Participants With Non-segmental VitiligoPhase 2/3 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Feb 2027A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIUPhase 2 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Studies
Open first, then newest update. How each study uses FXS5626 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIURecruitingPhase 2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07552012Written as FXS5626 tablet
- QT Interval Effects Study of Oral FXS5626 TabletsRecruitingPhase 1Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07695779Written as FXS5626 tablet
- Phase II/III Study of FXS5626 in Participants With Non-segmental VitiligoNot yet recruitingPhase 2/3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07840820Written as Intervention1: FXS5626 Tablets